TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00041756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-530742
Description: One 25 mg PG-530742 tablet, twice daily for for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet, twice daily for for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PG-530742
Description: One 50 mg PG-530742 tablet, twice daily for for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PG-530742
Description: 100 mg PG-530742 tablet, twice a day for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg PG-530742
Description: 200 mg PG-530742 tablet, twice a day for one year
Study: NCT01653808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elisio-210H
Description: comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-210H
Description: comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional hemodialysis
Description: comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: on line hemodiafiltration
Description: comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
Study: NCT04421742

Intervention type: DRUG
Intervention: Beclomethasone Dipropionate/Formoterol Fumarate
Description: BDP/FF NEXThaler® 100/6 μg b.i.d.
Study: NCT02799303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI
Description: Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSA testing
Description: Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
Study: NCT04399551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB OLI
Description: CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA 600 mg will be administered as intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV OLI
Description: RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: RPV LA 900 mg will be administered as IM injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Quality Improvement (CQI) calls
Description: CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
Study: NCT03880695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib+ Liposomal Doxorubicin
Description: Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
Study: NCT00742820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Acetate Oral Solution 667 mg per 5 mL
Description: Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Acetate 667 mg GelCaps
Description: Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcium Citrate 950 mg Caplets
Description: Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
Study: NCT01014975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human)
Description: Plasmin (Human), 20 mg, delivered through a catheter into a thrombus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human)
Description: Plasmin (Human), 40 mg, delivered through a catheter into a thrombus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human)
Description: Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
Study: NCT02122341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BackStop
Description: BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
Study: NCT01469455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT01
Description: DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions.
Study: NCT00633932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20mg once daily
Study: NCT03248609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milano grapes
Description: Milano grapes to test post-prandial glycemic response

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table grapes
Description: Table grapes to test post-prandial glycemic response

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grape juice
Description: Grape juice to test post-prandial glycemic response

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose beverage
Description: Standardized glucose beverage to test post-prandial glycemic response
Study: NCT00724139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: : APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel
Description: training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
Study: NCT02105441

Intervention type: DEVICE
Intervention: Cochlear implant
Description: Implantable hearing device
Study: NCT02611050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Multi-vessel Coronary Artery Disease Option Grid
Description: The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
Study: NCT01118455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Therapy
Description: Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Epileptic Drug (AED)
Description: Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
Study: NCT02751918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
Study: NCT02852018

Intervention type: GENETIC
Intervention: Identification of genetic polymorphisms

Intervention type: GENETIC
Intervention: Identification of genetic polymorphisms
Study: NCT05429658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
Study: NCT00981396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT (Emotional Freedom Techniques)
Description: EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT (Cognitive Behavioral Therapy)
Description: CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
Study: NCT04289701

Intervention type: OTHER
Intervention: Health Services for Systematic Hypertension Management
Description: The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~1. Healthcare provider training and patient education.~2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~5. Outcome and performance evaluation quarterly.~6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~7. Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers.
Study: NCT04025437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy alone
Description: Patients in this group will receive hepatectomy alone.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant radiotherapy
Description: Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
Study: NCT02396537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Administered intranasally prior to Midazolam administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Administered intranasally prior to Midazolam administration.
Study: NCT03774602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion and provision of RMNCH services
Description: Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
Study: NCT03361787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parentship- a multi dimensional intervention program to improve parental resilience
Description: Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model.
Study: NCT02534753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascor L 500® (Ascorbic Acid Injection, USP)
Description: A sterile, solution containing 500 mg ascorbic acid per mL
Study: NCT03056664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine drainage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine drainage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine drainage surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC injection 01
Description: Local MSC injection in peri-anal with a dose of 3×10E6/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC injection 02
Description: Local MSC injection in peri-anal with a dose of 6×10E6/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: NS injection instead of MSC
Study: NCT04239729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Website and Coaching
Description: The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
Study: NCT02199821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula with soybean oil, medium-chain triglycerides

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil formula commonly used in the hospital
Study: NCT02372760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BA by spray catheter (Olympus PW-205V)
Description: This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BA classic anesthesia
Description: This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: Both groups will receive lidocaine as the anesthesia for bronchoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Both groups will receive lidocaine as the anesthesia for bronchoscopy
Study: NCT00150995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Study: NCT03861520

Intervention type: DEVICE
Intervention: Midtrimester anomaly scan
Description: A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy

Intervention type: GENETIC
Intervention: Fetal Karyotyping
Description: Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
Study: NCT01842737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal treatment
Description: This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
Study: NCT02732626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Study: NCT03697382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Steps
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Steps
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Steps
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study: NCT02918734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobutton CL BTB
Description: ACL reconstruction with Endobutton CL BTB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal interference screw
Description: ACL reconstruction with metal interference screw
Study: NCT03360877

Intervention type: OTHER
Group type: OTHER
Intervention: Health-care associated infection (HCAI)
Description: Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
Study: NCT01884714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/high calorie meal
Description: All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
Study: NCT04619953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Postural Stability Training
Description: The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Motor Training
Description: The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
Study: NCT00335686

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
Description: Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Nevirapine (Viramune): 1 comp (200mg)/12h
Description: Nevirapine (Viramune): 1 comp (200mg)/12h
Study: NCT04164498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: exposure to music to investigate its effects on reducing noise adverse effects
Study: NCT02388932

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT02608905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
Study: NCT02492113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Description: Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ZEEP
Description: After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged.
Study: NCT03881319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gynecologic treatment
Description: Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose acupuncture
Description: Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)